Corcept Therapeutics Faces Major Setbacks: FDA Rejects Relacorilant, Key Patent Lost, and Profitability Declines

summarizeSummary

Corcept Therapeutics reported a significant decline in profitability for 2025, driven by an FDA Complete Response Letter for relacorilant in hypercortisolism and an appellate court affirming no patent infringement for Korlym, alongside a new securities class action lawsuit.

check_boxKey Events

• FDA Rejects Relacorilant NDA

  The FDA issued a Complete Response Letter on December 30, 2025, for relacorilant in hypercortisolism, requiring additional efficacy evidence, a significant setback for a key pipeline candidate.

• Appellate Court Affirms Key Patent Loss

  On February 19, 2026, the appellate court affirmed a ruling that Teva's generic Korlym does not infringe Corcept's patents, confirming a major blow to the company's intellectual property for its primary commercial product.

• New Securities Class Action Filed

  A lawsuit was initiated on February 20, 2026, alleging false and misleading statements regarding the relacorilant NDA, adding new legal risk.

• Profitability and Cash Flow Decline

  Net income decreased to $99.7 million in 2025 from $141.2 million in 2024, and net cash from operating activities fell to $142.0 million from $198.3 million, reflecting increased operating expenses and competitive pressures.

auto_awesomeAnalysis

This annual report highlights a challenging period for Corcept Therapeutics, marked by significant regulatory and legal setbacks that overshadow positive pipeline developments. The FDA's Complete Response Letter for relacorilant in hypercortisolism is a major blow, indicating a need for further clinical data and delaying a crucial potential growth driver. Concurrently, the appellate court's affirmation of no patent infringement for Korlym to Teva confirms a major blow to the company's intellectual property for its primary commercial product. The newly disclosed securities class action lawsuit adds further legal and reputational risk, directly tied to the relacorilant NDA outcome. These events, combined with a notable decline in net income and operating cash flow for the fiscal year 2025, suggest a difficult path ahead for the company. Investors should monitor the company's strategy for addressing the FDA's requirements for relacorilant, the impact of generic competition on Korlym sales, and the progress of the various legal proceedings.